Moreover, the clinical significance of the PAK4–AMPK pathway in sarcopenia is underscored by the finding that PAK4 protein levels and AMPKα2‐S491 phosphorylation were not only elevated but also negatively correlated with the skeletal muscle mass and grip strength in muscle tissues from sarcopenic patients compared with non‐sarcopenic individuals. The gene discussed is PRKAA1; the disease is sarcopenia.